Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$17.51 USD
-0.05 (-0.28%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $17.52 +0.01 (0.06%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CPRX 17.51 -0.05(-0.28%)
Will CPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Other News for CPRX
Catalyst Pharmaceuticals enters exclusive agreement with Kye Pharmaceuticals
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
Catalyst sells Canadian rights to Duchenne drug to Kye Pharma
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX): A Growth-Oriented Value Investment Opportunity